Department of Anaesthesia and Intensive Care Medicine, Ryhov County Hospital, Jönköping, Sweden.
Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
World J Surg Oncol. 2022 Mar 31;20(1):103. doi: 10.1186/s12957-022-02568-4.
Vascular access in cancer patients is of great importance in order to deliver tumour-specific therapy and continues to be so during exceptional conditions. This study aimed to examine the impact of the coronavirus disease 2019 pandemic on the care and complication rates associated with subcutaneous venous port (PORT) insertion in cancer treatment.
We retrospectively studied all adult cancer patients that received a PORT in 2020 at a Swedish county hospital, including insertion characteristics and in-dwell complication rates for up to 6 months after implantation; these estimates were compared with historic data.
Data from 257 patients, of which 56 were haematological patients, were included and compared with those of 168 patients in the control group. The group characteristics were similar, except for the inclusion of haematological patients in the study group. Insertion characteristics showed a shorter waiting time and higher rates of antibiotic and sedative use during the pandemic. The rates of postoperative haematoma and catheter occlusion during the study period were higher than otherwise. The rates of adverse events related to the PORT in the solid tumour group were comparable to those in the control group (18.4% vs. 14.9%). Patients with haematological malignancies were more likely to experience adverse events (37.5% vs. 18.4%) and deep venous thrombosis (7.1% vs. 1.0%) than those with solid tumours.
In conclusion, the present findings suggest that PORTs remain a safe venous access system even during a pandemic, indicating a robust vascular access service.
为了提供肿瘤特异性治疗，癌症患者的血管通路非常重要，在特殊情况下也是如此。本研究旨在探讨 2019 年冠状病毒病大流行对癌症治疗中皮下静脉港（PORT）植入相关护理和并发症发生率的影响。
我们回顾性研究了瑞典一家县医院 2020 年接受 PORT 的所有成年癌症患者，包括植入特征和植入后长达 6 个月的留置并发症发生率；这些估计值与历史数据进行了比较。
纳入了 257 例患者的数据，其中 56 例为血液系统患者，并与对照组的 168 例患者进行了比较。两组患者的特征相似，除了研究组中包括血液系统患者。植入特征显示，大流行期间等待时间更短，抗生素和镇静剂的使用率更高。研究期间术后血肿和导管堵塞的发生率高于其他时期。实体瘤组与对照组相比，PORT 相关不良事件的发生率相当（18.4% vs. 14.9%）。与实体瘤患者相比，血液系统恶性肿瘤患者发生不良事件（37.5% vs. 18.4%）和深静脉血栓（7.1% vs. 1.0%）的风险更高。
总之，目前的研究结果表明，即使在大流行期间，PORT 仍然是一种安全的静脉通路系统，这表明血管通路服务稳健。
